US Meningococcal Vaccines Market Assessed & Forecast in In-demand GlobalData Report Available at MarketPublishers.com

22 Jul 2013 • by Natalie Aster

LONDON – Meningococcal disease refers to an acute infection caused by the bacterium Neisseria meningitidis (also known as meningococcus). The impossibility to diagnose the disease promptly and effectively due to its sudden onset and severe symptoms is the reason why the meningococcal disease space is dominated by vaccines.

Presently, tetravalent conjugate vaccines like Sanofi’s Menactra and Novartis’ Menveo account for the lion’s share of global sales, with the US adolescent market being the key target segment. The growth in the meningococcal vaccines market is forecast to be mainly driven by the launch of vaccines against Neisseria meningitides serogroup B (serotype B vaccines), which address crucial unmet needs in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to capture market share during the forecast period.

In-demand report “PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData provides impartial insights into the meningococcal vaccines market landscape in the United States.

The study provides a comprehensive overview of meningococcal vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines, as well as reviews the competitive landscape. It gives detailed information on the key drugs in the US, including product description, safety and efficacy profiles and also a SWOT analysis. Sales forecast for the leading drugs in the US from 2012-2022 is available, too. Furthermore, the report analyses the impact of major events, as well as the drivers and restraints affecting the US meningococcal vaccines market.

Report Details:

PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 119
Price: US$ 4,995.00

Other Vaccines Market Reports by GlobalData Include:

• PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
• PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
• PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
• PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
• PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
• PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022

More in-demand reports by the publisher can be found at GlobalData page.

Contacts

MarketPublishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com